CHMP Backs Roche’s Susvimo for Wet AMD, European Commission Decision Pending

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Roche’s Susvimo (ranibizumab injection) 100 mg/mL for the treatment of wet age-related macular degeneration (AMD), bringing the therapy one step closer to authorization across the European Union. The recommendation covers use of Susvimo with the Contivue implant, a refillable ocular implant designed to provide continuous delivery of ranibizumab into the vitreous.

GA in Practice

A panel of experts discusses why they’ve moved toward earlier treatment for geographic atrophy and reviews real-world cases that illustrate the complexity of modern practice.

Geeta A. Lalwani, MD; Murtaza Adam, MD; and Carl J. Danzig, MD, FASRS

Retina Today

Retina specialists have been slowly becoming more comfortable treating patients with geographic atrophy (GA) since the US Food and Drug Administration (FDA) approvals of pegcetacoplan (Syfovre, Apellis/Biogen) and avacincaptad pegol (Izervay, Astellas) in 2023. At first, many of us took a cautious approach to integrating these drugs into our clinical algorithms as we waited to see how real-world patients would react to treatment. In 2026, we are treating patients with a wider variety of clinical presentations and, importantly, we are treating them earlier. To learn more about how and why my colleagues have embraced treatment of early GA, I sat down with Murtaza Adam, MD, and Carl J. Danzig, MD, for a roundtable discussion. We shared real-world cases from our clinics that illustrated the value of early intervention and recorded 3 podcast episodes where we challenged each other on how to treat a series of hypothetical patients whose “real-world” circumstances complicated easy clinical decision-making. Head to Eyetube.net to see our case presentations and listen to New Retina Radio to hear our perspectives. You’ll find ways to directly access the videos and podcasts scattered throughout this discussion. The roundtable below is adapted from our various discussions and has been edited for brevity and clarity. — Geeta Lalwani, MD ▶ Want to watch Drs.

Rare Disease Mystery Cases

Can you diagnose these unusual cases based on the examination and imaging?

Kenneth C. Fan, MD, MBA; Caroline C. Awh, MD; Nimesh A. Patel, MD; Marta Stevanovic, MD, MSc; Maria Emfietzoglou, MD; Demetrios Vavvas, MD, PhD; Mary V. Lang; Lisa A. Schimmenti, MD; and Brittni A. Scruggs, MD, PhD

Retina Today

A Proposed Medicare Policy Would Tie Our Hands in the Fight Against Glaucoma

Chuck Williamson Jr

Glaucoma Today

As an ophthalmic practice administrator, I see every day what it takes to deliver the interventional glaucoma care necessary to preserve sight. It is not a simple cookie-cutter approach. A proposed Medicare policy would make it harder still, replacing physician judgment with a rigid, one-size-fits-all sequence that ignores how differently this disease behaves from patient to patient. What the LCDs Would Restrict Five Medicare Administrative Contractors (MACs) have similar Local Coverage Determinations (LCDs) in the proposal stage and available for comment through July 4. At issue is coverage of the intracameral travoprost implant (iDose TR, Glaukos). If the LCDs become finalized, Medicare would not cover the procedural pharmaceutical unless patients first fail both a trial of selective laser trabeculoplasty (SLT) and two topical medications. The LCD would also bar physicians from placing the implant during a MIGS procedure, whether that MIGS procedure is performed alone or in combination with cataract surgery. If finalized, the LCDs would take decision-making out of the hands of physicians and replace individualized judgment with a fixed treatment sequence applied to every patient. One Treatment Pathway Does Not Fit Every Patient Glaucoma is a heterogeneous disease. It presents and progresses differently in each patient, and physicians need a full range of options to treat each case individually.

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava

Eyetube

Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyewire News

07.28.2026

CHMP Backs Roche’s Susvimo for Wet AMD, European Commission Decision Pending

07.28.2026

BostonSight Reports PROSE Treatment Improved Disease Stage and Visual Acuity in Neurotrophic Keratitis Study

07.28.2026

Claris Biotherapeutics Raises $118 Million to Advance Treatment Candidate for Limbal Stem Cell Deficiency

07.27.2026

Aravind Eye Care System, Alcon Launch Global Vitreoretinal Surgery Training Center in India

07.27.2026

Glaukos Completes Enrollment in US Pivotal Study of Preserflo MicroShunt for POAG

EyewireTV

07.22.2026

The Latest EyewireTV

PRIMA Retinal Implant Launched in Europe Following CE Mark

B+L Launches EyeGility Inserter Preloaded IOL Delivery System in US

Update on Clinical Development Milestone

Stocks

Cataract

MIGS Device Selection in Practice

Addressing Inflammatory Dry Eye

MIGS and Cataract Surgery

IJC Recap: Treating Inflammatory Dry Eye, an Emerging Option for Normal Tension Glaucoma, and the Role of Yag Laser Vitreolysis for Vitreous Floaters

Elara 900: Reinventing the Clinical Workhorse

Integrating MIGS Without Disrupting Efficiency

07.24.2026

Théa, Unither Pharmaceuticals Partner on Dedicated Ophthalmic Manufacturing Facility in France

07.21.2026

Pediatric Cataract Surgery May Alter Coordination of Ocular Growth, International Study Finds

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

07.17.2026

Moorfields and University College London Launch CADMUS Anterior Segment Imaging Dataset

Refractive

The Limits of Combining Phacoemulsification and MIGS

Exploring Nd:YAG Vitreolysis After Cataract Surgery for Symptomatic Eyes

Rethinking the Drop with iDose TR: Practice Implementation

Genetically Predisposed to Capsular Bag Instability

Netarsudil Joins the Glaucoma Toolbox

Interventional Glaucoma: A Collaborative Care Model for the Future of Glaucoma Management

07.23.2026

iVeena Reports FDA Alignment on Phase 2 Development Plan for Pediatric Myopia Candidate IVMED-85

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

07.17.2026

Moorfields and University College London Launch CADMUS Anterior Segment Imaging Dataset

07.17.2026

iVeena Reports Favorable Phase 1 Safety Data for Investigational Pediatric Myopia Therapy IVMED-85

Stay Updated

Follow Eyewire News

Retina

GA in Practice

ARVO '26: TKIs for Wet AMD and How We Got to the AI Era of Research

Rare Disease Mystery Cases

Barriers to Care, Patient Education, and Treatment Decisions in Geographic Atrophy

Beyond One-Size-Fits-All: The Move Toward Personalized Vitreoretinal Therapy

Biomarkers, Imaging, and Early Treatment Decisions in Geographic Atrophy

07.28.2026

CHMP Backs Roche’s Susvimo for Wet AMD, European Commission Decision Pending

07.27.2026

Aravind Eye Care System, Alcon Launch Global Vitreoretinal Surgery Training Center in India

07.24.2026

Topcon Receives CE Mark for GAIA Ultra-Widefield Retinal Imaging System

07.24.2026

Study: Mediterranean Diet Linked to Slower AMD Progression Across Disease Stages

Glaucoma

A Proposed Medicare Policy Would Tie Our Hands in the Fight Against Glaucoma

Endoscopic Cyclophotocoagulation

Alloflo Cyclodialysis Cleft Scleral Implants

Canaloplasty and ECP

Seen & Heard

Three Real-World Scenarios in Which a Minimally Invasive Approach Prevailed

07.27.2026

Glaukos Completes Enrollment in US Pivotal Study of Preserflo MicroShunt for POAG

07.24.2026

Théa, Unither Pharmaceuticals Partner on Dedicated Ophthalmic Manufacturing Facility in France

07.21.2026

Fundamental XR, Orbis Report Early Success of VR Ophthalmic Training Program Across Africa

07.17.2026

Glaucoma UK Launches Nationwide Patient Survey Targeting 10,000 Responses